Basic Information
RNALocate ID: | RLID:01001378 |
RNA Symbol: | hsa-miR-30a-5p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-30a |
RNA ID: | miRBase:MIMAT0000087 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001379 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001380 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001381 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001382 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001383 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:11000903 | Exosome | Primary dendritic cells | 21505438 |
RLID:11000904 | Exosome | Renal cancer cells | 21670082 |
RLID:11000905 | Exosome | Brain tissue | 23382797 |
RLID:11000906 | Exosome | Plasma | 23663360 |
RLID:11000907 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000908 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000909 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000910 | Microvesicle | Plasma | 23077538 |
RLID:11000911 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000912 | Microvesicle | Follicular fluid | 23666971 |
RLID:11000913 | Microvesicle | Hepatoma cells | 23771658 |
RLID:21000215 | Cytoplasmic stress granule | HeLa cells | 28488892 |
RLID-D:11000023 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Endothelial cells|Epithelial cells|Kidney tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000286 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-30a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-36677 |
MNDR | hsa-miR-30a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-36678 |
MNDR | hsa-miR-30a-5p | Colorectal adenoma | MNDR-E-MI-36679 |
MNDR | hsa-miR-30a-5p | Oral squamous cell carcinoma | MNDR-E-MI-36680 |
MNDR | hsa-miR-30a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-36681 |
MNDR | hsa-miR-30a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-36682 |
MNDR | hsa-miR-30a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-36683 |
MNDR | hsa-miR-30a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-36684 |
MNDR | hsa-miR-30a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-36685 |
MNDR | hsa-miR-30a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-36686 |
MNDR | hsa-miR-30a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-36687 |
MNDR | hsa-miR-30a-5p | Triple negative breast cancer | MNDR-E-MI-36688 |
MNDR | hsa-miR-30a-5p | Lupus nephritis | MNDR-E-MI-36689 |
MNDR | hsa-miR-30a-5p | Thyroid carcinoma anaplastic | MNDR-E-MI-36690 |
MNDR | hsa-miR-30a-5p | Dermatomyositis | MNDR-E-MI-36691 |
MNDR | hsa-miR-30a-5p | Prostate cancer | MNDR-E-MI-36692 |
MNDR | hsa-miR-30a-5p | Gastric cancer | MNDR-E-MI-36693 |
MNDR | hsa-miR-30a-5p | Gastric lymphoma | MNDR-E-MI-36694 |
MNDR | hsa-miR-30a-5p | Alzheimer disease | MNDR-E-MI-36695 |
MNDR | hsa-miR-30a-5p | Bladder cancer | MNDR-E-MI-36696 |
MNDR | hsa-miR-30a-5p | Esophageal carcinoma | MNDR-E-MI-36697 |
MNDR | hsa-miR-30a-5p | Sarcoma | MNDR-E-MI-36698 |
MNDR | hsa-miR-30a-5p | Duchenne muscular dystrophy | MNDR-E-MI-36699 |
MNDR | hsa-miR-30a-5p | Seizures | MNDR-E-MI-36700 |
MNDR | hsa-miR-30a-5p | Head and neck cancer | MNDR-E-MI-36701 |
MNDR | hsa-miR-30a-5p | Leukemia | MNDR-E-MI-36702 |
MNDR | hsa-miR-30a-5p | Huntington disease | MNDR-E-MI-36703 |
MNDR | hsa-miR-30a-5p | Chorea | MNDR-E-MI-36704 |
MNDR | hsa-miR-30a-5p | Cardiovascular disease | MNDR-E-MI-36705 |
MNDR | hsa-miR-30a-5p | Moyamoya disease | MNDR-E-MI-36706 |
MNDR | hsa-miR-30a-5p | Brain cancer | MNDR-E-MI-36707 |
MNDR | hsa-miR-30a-5p | Uterine fibroid | MNDR-E-MI-36708 |
MNDR | hsa-miR-30a-5p | Lung cancer | MNDR-E-MI-36709 |
MNDR | hsa-miR-30a-5p | Down syndrome | MNDR-E-MI-36710 |
MNDR | hsa-miR-30a-5p | Parkinson disease | MNDR-E-MI-36711 |
MNDR | hsa-miR-30a-5p | Colon carcinoma | MNDR-E-MI-36712 |
MNDR | hsa-miR-30a-5p | Basal-like breast cancer | MNDR-E-MI-36713 |
MNDR | hsa-miR-30a-5p | Squamous cell carcinoma | MNDR-E-MI-36714 |
MNDR | hsa-miR-30a-5p | Thyroid cancer | MNDR-E-MI-36715 |
MNDR | hsa-miR-30a-5p | Pituitary neoplasms | MNDR-E-MI-36716 |
MNDR | hsa-miR-30a-5p | Pancreatic cancer | MNDR-E-MI-36717 |
MNDR | hsa-miR-30a-5p | Melanoma | MNDR-E-MI-36718 |
MNDR | hsa-miR-30a-5p | Rectum adenocarcinoma | MNDR-E-MI-36719 |
MNDR | hsa-miR-30a-5p | Nephroblastoma | MNDR-E-MI-36720 |
MNDR | hsa-miR-30a-5p | Colon cancer | MNDR-E-MI-36721 |
MNDR | hsa-miR-30a-5p | Ischemic attack transient | MNDR-E-MI-36722 |
MNDR | hsa-miR-30a-5p | Colon adenocarcinoma | MNDR-E-MI-36723 |
MNDR | hsa-miR-30a-5p | Multiple sclerosis | MNDR-E-MI-36724 |
MNDR | hsa-miR-30a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-36725 |
MNDR | hsa-miR-30a-5p | Familial ovarian cancer | MNDR-E-MI-36726 |
MNDR | hsa-miR-30a-5p | Acromegaly | MNDR-E-MI-36727 |
MNDR | hsa-miR-30a-5p | Prostate adenocarcinoma | MNDR-E-MI-36728 |
MNDR | hsa-miR-30a-5p | Carcinoma ductal breast | MNDR-E-MI-36729 |
MNDR | hsa-miR-30a-5p | Balkan nephropathy | MNDR-E-MI-36730 |
MNDR | hsa-miR-30a-5p | Glioblastoma | MNDR-E-MI-36731 |
MNDR | hsa-miR-30a-5p | Glioma | MNDR-E-MI-36732 |
MNDR | hsa-miR-30a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-36733 |
MNDR | hsa-miR-30a-5p | Temporal lobe epilepsy | MNDR-E-MI-36734 |
MNDR | hsa-miR-30a-5p | Osteosarcoma | MNDR-E-MI-36735 |
MNDR | hsa-miR-30a-5p | Liposarcoma | MNDR-E-MI-36736 |
MNDR | hsa-miR-30a-5p | Carotid artery disease | MNDR-E-MI-36737 |
MNDR | hsa-miR-30a-5p | Inclusion body myositis | MNDR-E-MI-36738 |
MNDR | hsa-miR-30a-5p | Meningioma | MNDR-E-MI-36739 |
MNDR | hsa-miR-30a-5p | Liver cancer | MNDR-E-MI-36740 |
MNDR | hsa-miR-30a-5p | Uterine cancer | MNDR-E-MI-36741 |
MNDR | hsa-miR-30a-5p | Cervical adenocarcinoma | MNDR-E-MI-36742 |
MNDR | hsa-miR-30a-5p | Gastric adenocarcinoma | MNDR-E-MI-36743 |
MNDR | hsa-miR-30a-5p | Pituitary adenoma | MNDR-E-MI-36744 |
MNDR | hsa-miR-30a-5p | Lung squamous cell carcinoma | MNDR-E-MI-36745 |
MNDR | hsa-miR-30a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-36746 |
MNDR | hsa-miR-30a-5p | Lung adenocarcinoma | MNDR-E-MI-36747 |
MNDR | hsa-miR-30a-5p | Adrenocortical cancer | MNDR-E-MI-36748 |
MNDR | hsa-miR-30a-5p | Thyroid carcinoma | MNDR-E-MI-36749 |
MNDR | hsa-miR-30a-5p | Bladder urothelial carcinoma | MNDR-E-MI-36750 |
MNDR | hsa-miR-30a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-36751 |
MNDR | hsa-miR-30a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-36752 |
MNDR | hsa-miR-30a-5p | Carcinoma renal cell | MNDR-E-MI-36753 |
MNDR | hsa-miR-30a-5p | Papillary renal cell carcinoma | MNDR-E-MI-36754 |
MNDR | hsa-miR-30a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-36755 |
MNDR | hsa-miR-30a-5p | Large cell carcinoma | MNDR-E-MI-36756 |
MNDR | hsa-miR-30a-5p | Biliary tract cancer | MNDR-E-MI-36757 |
MNDR | hsa-miR-30a-5p | Cholangiocarcinoma | MNDR-E-MI-36758 |
MNDR | hsa-miR-30a-5p | Esophageal cancer | MNDR-E-MI-36759 |
MNDR | hsa-miR-30a-5p | Prolactinoma | MNDR-E-MI-36760 |
MNDR | hsa-miR-30a-5p | Lung small cell carcinoma | MNDR-E-MI-36761 |
MNDR | hsa-miR-30a-5p | Schizophrenia | MNDR-E-MI-36762 |
MNDR | hsa-miR-30a-5p | Variant creutzfeldt-jakob disease | MNDR-E-MI-36763 |
MNDR | hsa-miR-30a-5p | Synovial sarcoma | MNDR-E-MI-36764 |
MNDR | hsa-miR-30a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-36765 |
MNDR | hsa-miR-30a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-36766 |
MNDR | hsa-miR-30a-5p | Breast invasive carcinoma | MNDR-E-MI-36767 |
MNDR | hsa-miR-30a-5p | Hepatocellular carcinoma | MNDR-E-MI-36768 |
MNDR | hsa-miR-30a-5p | Familiar ovarian carcinoma | MNDR-E-MI-36769 |
MNDR | hsa-miR-30a-5p | B-cell lymphoma | MNDR-E-MI-36770 |
MNDR | hsa-miR-30a-5p | Rheumatoid arthritis | MNDR-E-MI-36771 |
MNDR | hsa-miR-30a-5p | T-cell leukemia | MNDR-E-MI-36772 |
MNDR | hsa-miR-30a-5p | Abdominal aortic aneurysm | MNDR-E-MI-36773 |
MNDR | hsa-miR-30a-5p | Osteoarthritis | MNDR-E-MI-36774 |
MNDR | hsa-miR-30a-5p | Chronic myelogenous leukemia | MNDR-E-MI-36775 |
MNDR | hsa-miR-30a-5p | Hodgkin lymphoma | MNDR-E-MI-36776 |
MNDR | hsa-miR-30a-5p | Burkitt lymphoma | MNDR-E-MI-36777 |
MNDR | hsa-miR-30a-5p | Tonsil cancer | MNDR-E-MI-36778 |
MNDR | hsa-miR-30a-5p | Neuromyelitis optica | MNDR-E-MI-36779 |
MNDR | hsa-miR-30a-5p | Colorectal cancer | MNDR-E-MI-36780 |
MNDR | hsa-miR-30a-5p | Nasopharynx carcinoma | MNDR-E-MI-36781 |
MNDR | hsa-miR-30a-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-36782 |
MNDR | hsa-miR-30a-5p | Cardiomegaly | MNDR-E-MI-36783 |
MNDR | hsa-miR-30a-5p | Nasopharyngeal cancer | MNDR-E-MI-36784 |
MNDR | hsa-miR-30a-5p | Prostatic neoplasms | MNDR-E-MI-36785 |
MNDR | hsa-miR-30a-5p | Pseudorabies | MNDR-E-MI-36786 |
MNDR | hsa-miR-30a-5p | Sleep deprivation | MNDR-E-MI-36787 |
MNDR | hsa-miR-30a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-36788 |
MNDR | hsa-miR-30a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-36789 |
MNDR | hsa-miR-30a-5p | Venous thromboembolism | MNDR-E-MI-36790 |
MNDR | hsa-miR-30a-5p | Stroke lacunar | MNDR-E-MI-36791 |
MNDR | hsa-miR-30a-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-36792 |
MNDR | hsa-miR-30a-5p | Breast cancer her3+ negative | MNDR-E-MI-36793 |
MNDR | hsa-miR-30a-5p | Duke A | MNDR-E-MI-36794 |
MNDR | hsa-miR-30a-5p | Glomerular disease | MNDR-E-MI-36795 |
MNDR | hsa-miR-30a-5p | Low grade dysplastic nodule | MNDR-E-MI-36796 |
MNDR | hsa-miR-30a-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-36797 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABL1 | Homo sapiens | RR00026978 |
TOP